Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
Portfolio Pulse from
Syros Pharmaceuticals announced that their Phase 3 trial of tamibarotene for higher-risk myelodysplastic syndrome did not meet its primary endpoint. This could impact investor sentiment negatively.
November 12, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in combination with azacitidine for HR-MDS patients did not achieve the primary endpoint of complete response rate, which could lead to negative investor sentiment.
The failure to meet the primary endpoint in a Phase 3 trial is a significant setback for a biopharmaceutical company, as it may delay or prevent the drug's approval and commercialization. This news is likely to lead to a negative short-term impact on Syros Pharmaceuticals' stock price due to potential loss of investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100